Coverage
-
May 14, 2019
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a patent on Johnson & Johnson's blockbuster prostate cancer drug Zytiga, while leaving open a larger question about the reach of estoppel in America Invents Act reviews.
7 other articles on this case.
View all »